TrialLeukemia2022

Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.

Yajing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.